Literature DB >> 25035209

Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.

Benjamin A Greenberger1, Margaret B Pulsifer2, David H Ebb3, Shannon M MacDonald4, Robin M Jones5, William E Butler6, Mary S Huang3, Karen J Marcus7, Jennifer A Oberg8, Nancy J Tarbell9, Torunn I Yock10.   

Abstract

PURPOSE/OBJECTIVE(S): Primary low-grade gliomas are common brain tumors of childhood, many of which require radiation therapy (RT) as definitive treatment. Increased conformality of RT could decrease the incidence and severity of late effects. We report our experience with 32 pediatric patients treated with proton RT. METHODS AND MATERIALS: Thirty-two pediatric patients with low-grade gliomas of the brain or spinal cord were treated with proton RT from 1995 to 2007. Sixteen patients received at least 1 regimen of chemotherapy before definitive RT. The median radiation dose was 52.2 GyRBE (48.6-54 GyRBE).
RESULTS: The median age at treatment was 11.0 years (range, 2.7-21.5 years), with a median follow-up time of 7.6 years (range, 3.2-18.2 years). The 6-year and 8-year rates of progression-free survival were 89.7% and 82.8%, respectively, with an 8-year overall survival of 100%. For the subset of patients who received serial neurocognitive testing, there were no significant declines in Full-Scale Intelligence Quotient (P=.80), with a median neurocognitive testing interval of 4.5 years (range, 1.2-8.1 years) from baseline to follow-up, but subgroup analysis indicated some significant decline in neurocognitive outcomes for young children (<7 years) and those with significant dose to the left temporal lobe/hippocampus. The incidence of endocrinopathy correlated with a mean dose of ≥40 GyRBE to the hypothalamus, pituitary, or optic chiasm. Stabilization or improvement of visual acuity was achieved in 83.3% of patients at risk for radiation-induced injury to the optic pathways.
CONCLUSIONS: This report of late effects in children with low-grade gliomas after proton RT is encouraging. Proton RT appears to be associated with good clinical outcome, especially when the tumor location allows for increased sparing of the left temporal lobe, hippocampus, and hypothalamic-pituitary axis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25035209     DOI: 10.1016/j.ijrobp.2014.04.053

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  49 in total

1.  Treatment burden and long-term health deficits of patients with low-grade gliomas or glioneuronal tumors diagnosed during the first year of life.

Authors:  Anthony P Y Liu; Camden Hastings; Shengjie Wu; Johnnie K Bass; Andrew M Heitzer; Jason Ashford; Robert Vestal; Mary E Hoehn; Yahya Ghazwani; Sahaja Acharya; Heather M Conklin; Frederick Boop; Thomas E Merchant; Amar Gajjar; Ibrahim Qaddoumi
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

2.  Outcomes and acute toxicities of proton therapy for pediatric atypical teratoid/rhabdoid tumor of the central nervous system.

Authors:  Susan L McGovern; M Fatih Okcu; Mark F Munsell; Nancy Kumbalasseriyil; David R Grosshans; Mary F McAleer; Murali Chintagumpala; Soumen Khatua; Anita Mahajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-11       Impact factor: 7.038

3.  Conformal Radiation Therapy for Pediatric Patients with Low-Grade Glioma: Results from the Children's Oncology Group Phase 2 Study ACNS0221.

Authors:  Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-10       Impact factor: 7.038

Review 4.  The use and efficacy of chemotherapy and radiotherapy in children and adults with pilocytic astrocytoma.

Authors:  Matthew W Parsons; Nicholas S Whipple; Matthew M Poppe; Joe S Mendez; Donald M Cannon; Lindsay M Burt
Journal:  J Neurooncol       Date:  2020-10-31       Impact factor: 4.130

5.  A comparison study assessing neuropsychological outcome of patients with post-operative pediatric cerebellar mutism syndrome and matched controls after proton radiation therapy.

Authors:  Julie A Grieco; Annah N Abrams; Casey L Evans; Torunn I Yock; Margaret B Pulsifer
Journal:  Childs Nerv Syst       Date:  2019-07-19       Impact factor: 1.475

6.  Local failure in parameningeal rhabdomyosarcoma correlates with poor response to induction chemotherapy.

Authors:  Matthew M Ladra; Henry C Mandeville; Andrzej Niemierko; Timothy P Padera; Alison M Friedmann; Shannon M MacDonald; David Ebb; Yen-Lin Chen; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-08       Impact factor: 7.038

7.  Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis.

Authors:  Sahaja Acharya; Jo-Fen Liu; Ruth G Tatevossian; Jason Chiang; Ibrahim Qaddoumi; Amar Gajjar; David Walker; Julie H Harreld; Thomas E Merchant; David W Ellison
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

8.  Cognitive mediators of adaptive functioning outcomes in survivors of pediatric brain tumors treated with proton radiotherapy.

Authors:  Alexandra K Roth; M Douglas Ris; Jessica Orobio; Judy Xue; Anita Mahajan; Arnold C Paulino; David Grosshans; M Fatih Okcu; Murali Chintagumpala; Lisa S Kahalley
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

Review 9.  Proton therapy for paediatric CNS tumours - improving treatment-related outcomes.

Authors:  Vinai Gondi; Torunn I Yock; Minesh P Mehta
Journal:  Nat Rev Neurol       Date:  2016-05-20       Impact factor: 42.937

10.  Early Cognitive Outcomes Following Proton Radiation in Pediatric Patients With Brain and Central Nervous System Tumors.

Authors:  Margaret B Pulsifer; Roshan V Sethi; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-06-14       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.